AP 2. Symbiosis: Ecorationale for bacterial isolation and drug screening

AP2.共生 摘要 PMS-ICBG专注于与软体动物相关的微生物作为新的生物活性来源 分子。在许多情况下，细菌共生体高度适应宿主，并具有 与寄主和栖息地的其他生物之间的复杂相互作用。这些分子是 在这些相互作用中使用的是通过进化选择的有用活动，以及 对宿主的毒性低，因此是药物开发的理想候选者。在我们的过去 研究我们对软体动物共生的一系列发现为我们的研究提供了信息 药物，让我们深入了解软体动物的生物多样性。在这个项目中，我们将调查 软体动物的微生物群落，研究与之相关的微生物之间的相互作用 ，并发现软体动物共生体生物活性分子的空间分布 了解它们在共生中的作用。这些研究的见解将被用来指导 药物发现努力设计细菌分离方法，选择可能产生细菌的菌株 有价值的化合物和诱人的代谢物产生。美联社由玛戈·海古德领导， 丹尼尔·迪斯特尔、埃里克·施密特、中广明和罗伯塔·奥康纳参与其中。

AP2. Symbiosis Summary PMS-ICBG focuses on microbes associated with mollusks as sources of novel bioactive molecules. In many cases, bacterial symbionts are highly adapted to their host, and have complex interactions with their hosts and other organisms in the habitat. Molecules that are employed in these interactions have been selected through evolution for useful activities, and low toxicity to the host, and thus are ideal candidates for drug development. In our past research we have made a series of discoveries about mollusk symbiosis that inform our search for drugs, and give us insight into the biodiversity of mollusks. In this project we will investigate the microbial communities of mollusks, study the interactions among microbes associated with mollusks, and discover the spatial distribution of mollusk symbiont bioactive molecules to understand their roles in the symbiosis. Insights from these studies will be used to guide the drug discovery efforts in designing bacterial isolation methods, selecting strains likely to produce valuable compounds, and eliciting metabolite production. This AP is led by Margo Haygood, with participation from Daniel Distel, Eric Schmidt, Hiroaki Naka and Roberta O'Connor.